ImmunityBio, Inc. $IBRX Shares Acquired by Swiss National Bank

Swiss National Bank lifted its stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 49.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 410,400 shares of the company’s stock after acquiring an additional 136,400 shares during the quarter. Swiss National Bank’s holdings in ImmunityBio were worth $1,235,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in IBRX. Vanguard Group Inc. increased its stake in shares of ImmunityBio by 17.4% during the first quarter. Vanguard Group Inc. now owns 20,344,554 shares of the company’s stock valued at $61,237,000 after acquiring an additional 3,016,325 shares during the period. Woodline Partners LP increased its stake in shares of ImmunityBio by 682.7% during the fourth quarter. Woodline Partners LP now owns 3,442,440 shares of the company’s stock valued at $8,813,000 after acquiring an additional 3,002,622 shares during the period. Tang Capital Management LLC acquired a new position in ImmunityBio in the fourth quarter worth approximately $7,204,000. Marshall Wace LLP acquired a new position in ImmunityBio in the fourth quarter worth approximately $615,000. Finally, Brevan Howard Capital Management LP acquired a new position in ImmunityBio in the fourth quarter worth approximately $255,000. Institutional investors and hedge funds own 8.58% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on IBRX shares. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of ImmunityBio in a research report on Wednesday, June 4th. Piper Sandler upgraded shares of ImmunityBio from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $4.25 to $5.00 in a research report on Tuesday, May 20th. Finally, D. Boral Capital restated a “buy” rating and issued a $24.00 price target on shares of ImmunityBio in a research report on Thursday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating and four have given a Buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $10.75.

ImmunityBio Stock Performance

NASDAQ IBRX opened at $2.25 on Tuesday. ImmunityBio, Inc. has a twelve month low of $1.83 and a twelve month high of $7.48. The stock has a market cap of $2.13 billion, a price-to-earnings ratio of -4.69 and a beta of 0.12. The firm’s 50 day moving average price is $2.64 and its two-hundred day moving average price is $2.76.

ImmunityBio (NASDAQ:IBRX) last issued its earnings results on Tuesday, August 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). The company had revenue of $26.43 million for the quarter, compared to analyst estimates of $21.95 million. On average, research analysts forecast that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.